BefejeződöttFázis nélkül
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study
A legfontosabb adatok
- Ki végzi
- Spectral Diagnostics (US) Inc.
- Hol
- Ann Arbor, Atlanta, Birmingham, Boulder, Camden, Charleston, Chattanooga, Houston, Little Rock, New York, Piscataway, Pittsburgh, Rochester, San Antonio, San Francisco, Shreveport, Springfield, Stony Brook és Washington D.C. (Egyesült Államok)Mind a 20 helyszín megnézése
- Azonosító
- Állapot
- Befejeződött
- Résztvevők
- 157 fő vett részt
- Kezdés
- 2020. jan. 9.
- Befejezés
- 2026. febr. 10.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
- A vizsgált kezelések
- Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge
- A regiszteradat frissítve
- 2026. október 13.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 26 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥18 years of age
- Hypotension requiring vasopressor support: Requirement for at least one of the vasopressors listed below, at the dose shown below, for at least 2 continuous hours and no more than 30 hours; Norepinephrine > 0.05mcg/kg/min; Dopamine > 10 mcg/kg/min; Phenylephrine > 0.4 mcg/kg/min; Epinephrine > 0.05 mcg/kg/min; Vasopressin > 0.03 units/min; Vasopressin (any dose) in combination with another vasopressor listed above
- The subject must have received intravenous fluid resuscitation of a minimum of 30mL/kg administered within 24 hours of eligibility
- Documented or suspected infection defined as definitive or empiric intravenous antibiotic administration
- The subject must have a screening multi-organ dysfunction score (MODS) >9 OR a sequential organ failure assessment (SOFA) >11, in the event a complete MODS cannot be obtained due to missing measurements
- Endotoxin Activity Assay between ≥ 0.60 to <0.90 EA units
- Evidence of at least 1 of the following criteria for new onset organ dysfunction that is considered to be due to the acute illness:; Requirement for positive pressure ventilation via an endotracheal tube or tracheostomy tube; Thrombocytopenia defined as acute onset of platelet count <150,000µ/L or a reduction of 50% from prior known levels; Acute oliguria defined as urine output <0.5mL/kg/hr for at least 6 hours despite adequate fluid resuscitation
Ki nem vehet részt
- Inability to achieve or maintain a minimum mean arterial pressure (MAP) of ≥ 65mmHg despite vasopressor therapy and fluid resuscitation
- Subject is currently enrolled in an investigational drug or device trial
- Subject has been previously enrolled in the current trial
- Subject has end-stage renal disease and requires chronic dialysis
- Subject has had an acute myocardial infarction (AMI) within the past 4 weeks
- Subject has uncontrolled hemorrhage (acute blood loss requiring > 3 UPC in the past 24 hours)
- Known hypersensitivity to Polymyxin B
- Subject has known sensitivity or allergy to heparin or has a history of heparin associated thrombocytopenia (H.I.T.)
- Any other condition, that in the opinion of the investigator, would preclude the subject from being a suitable candidate for enrollment, such as end-stage chronic illness (eg. lack of source control and bowel necrosis) with no reasonable expectation of survival to hospital discharge
- There is clinical support for non-septic shock such as:; Acute pulmonary embolus; Transfusion reaction; Severe congestive heart failure (e.g. NYHA Class IV, ejection fraction < 35%)
- Subject has severe granulocytopenia (leukocyte count less than 500 cells/mm3) or severe thrombocytopenia (platelet count less than 30,000 cells/mm3)
- HIV infection in association with a last known or suspected CD4 count of <50/mm3
- Inability to obtain an informed consent from the subject, family member or an authorized surrogate
- Lack of commitment for full medical support
- Subject has had chest compressions as part of CPR during this hospitalization without immediate return to communicative state
- Major trauma within 36 hours of screening
- Subject's baseline state is non-communicative
- Subject has sustained extensive third-degree burns within the past 7 days
- Body weight < 35 kg (77 pounds)
Helyszínek itt: Egyesült Államok
- University of MichiganAnn Arbor, Egyesült Államok
- Emory UniversityAtlanta, Egyesült Államok
- University of Alabama at BirminghamBirmingham, Egyesült Államok
- Pulmonary AssociatesBoulder, Egyesült Államok
- Cooper Health SystemCamden, Egyesült Államok
- Medical University of South CarolinaCharleston, Egyesült Államok
- CHI MemorialChattanooga, Egyesült Államok
- Parkridge HospitalChattanooga, Egyesült Államok
- The University of Texas Health Science Center at HoustonHouston, Egyesült Államok
- University of Arkansas for Medical SciencesLittle Rock, Egyesült Államok
- Mt Sinai HospitalNew York, Egyesült Államok
- Rutgers, the State University of New JerseyPiscataway, Egyesült Államok
- UPMCPittsburgh, Egyesült Államok
- Mayo ClinicRochester, Egyesült Államok
- Institute for Extracorporeal Life SupportSan Antonio, Egyesült Államok
- University of California San FranciscoSan Francisco, Egyesült Államok
- Louisiana State University Health ShreveportShreveport, Egyesült Államok
- Baystate Medical CenterSpringfield, Egyesült Államok
- Stony Brook UniversityStony Brook, Egyesült Államok
- George Washington UniversityWashington D.C., Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
Prospective, multicenter, randomized, open-label study of standard of care plus the PMX cartridge versus standard of care alone in patients with endotoxemic septic shock
A vizsgálat 2 csoportja
- PMX TreatmentA vizsgált kezelés
Standard medical care for septic shock plus treatment with the PMX cartridge (twice approximately 24 hours apart)
Kezelés: Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge
- ControlNincs vizsgálati kezelés, összehasonlításként
Standard medical care alone
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Prospective, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of PMX Cartridge in Addition to Standard Medical Care for Patients With Endotoxemic Septic Shock
- Publikációk
- Polymyxin B haemoadsorption in endotoxic septic shock (Tigris): a multicentre, open-label, Bayesian, randomised, controlled, phase 3 trial.The Lancet. Respiratory medicine, 2026
- A regiszteradat frissítve
- 2026. október 13.